Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Gene and cell cycle effects elucidated for NB-1011

July 4, 2001

SafeScience to create joint venture with Elan for phase II anticancer agent

July 3, 2001

Additional beneficial effects emerge for SERM Sch-57068 (EM-652) in preclinical studies

July 3, 2001

ImClone Systems begins fast track approval process for colorectal cancer agent

July 3, 2001

Liver-targeted complexes of cisplatin and bile acids designed by Spanish group

July 3, 2001

FDA grants fast track designation for irofulven in pancreatic cancer

July 2, 2001

Mode of action of Oxigene's CA4P supported by preclinical data

July 2, 2001

Matrix commences new phase II IntraDose study for primary liver cancer

July 2, 2001

TLK-286 enters phase II trial for non-small cell lung cancer

July 2, 2001

New data for Gleevec show increase in CML response rates over time

June 29, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...